Kintara Therapeutics Inc. (KTRA)
$0.23
$-7.82
(-97.20%)
As on 17-Oct-2024 19:49EDT
Market cap
$12 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
7.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-3.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1.4
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
55,660,600
10 Years Aggregate
CFO
$-97.76 Mln
EBITDA
$8,290,586.27 Mln
Net Profit
$8,290,563.01 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Kintara Therapeutics (KTRA)
| -96.2 | -96.2 | -97.8 | -99.8 | -94.7 | -80.4 | -71.1 |
|
BSE Sensex*
| -10.9 | -4.9 | -8.9 | -7.6 | 6.9 | 8.3 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Kintara Therapeutics (KTRA)
| -97.5 | -73.0 | -60.2 | 85.6 | -79.8 | -68.4 | -65.8 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Kintara Therapeutics (KTRA)
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a... DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California. Read more
-
President, CEO, Interim CFO & Chairman of the Board
Mr. Robert E. Hoffman B.B.A., CPA
-
President, CEO, Interim CFO & Chairman of the Board
Mr. Robert E. Hoffman B.B.A., CPA
-
Headquarters
San Diego, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Kintara Therapeutics (KTRA)
What is the current share price of Kintara Therapeutics Inc (KTRA) Today?
The share price of Kintara Therapeutics Inc (KTRA) is $0.23 (NASDAQ) as of 17-Oct-2024 19:49 EDT. Kintara Therapeutics Inc (KTRA) has given a return of -94.7% in the last 3 years.
What is the current PB & PE ratio of Kintara Therapeutics Inc (KTRA)?
Since, TTM earnings of Kintara Therapeutics Inc (KTRA) is negative, P/E ratio is not available.
The P/B ratio of Kintara Therapeutics Inc (KTRA) is 7.81 times as on 18-Oct-2024, a 91 premium to its peers’ median range of 4.08 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
What is the 52 Week High and Low of Kintara Therapeutics Inc (KTRA)?
The 52-week high and low of Kintara Therapeutics Inc (KTRA) are Rs -- and Rs -- as of 24-May-2026.
What is the market cap of Kintara Therapeutics Inc (KTRA)?
Kintara Therapeutics Inc (KTRA) has a market capitalisation of $ 12 Mln as on 18-Oct-2024. As per SEBI classification, it is a Small Cap company.
Should I invest in Kintara Therapeutics Inc (KTRA)?
Before investing in Kintara Therapeutics Inc (KTRA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.